stockrowJohnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.
- Revenue
- +5.86%
- EPS
- −95.8%
- Free cash flow
- −21.4%
- Total debt
- −9.16%
Quarter to September 2026, against a year earlier
Follow JNJ
Alert me
Johnson & Johnson (JNJ) Return on assets
Johnson & Johnson's return on assets over the twelve months to 30 September 2026 was 8.25%, down 5.9 percentage points from fiscal 2025 (14.1%). Over the past ten years it has ranged from 0.87% (fiscal 2017) to 19.8% (fiscal 2023); the current reading is higher than 91% of that period. That is above the Drug Manufacturers General industry median of 2.28% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 14.1% | 6.04 |
| FY2024 | 8.09% | (11.72) |
| FY2023 | 19.8% | 10.10 |
| FY2022 | 9.71% | (1.99) |
| FY2021 | 11.7% | 2.85 |
| FY2020 | 8.85% | (0.88) |
| FY2019 | 9.73% | (0.13) |
| FY2018 | 9.86% | 8.99 |
| FY2017 | 0.87% | (11.18) |
| FY2016 | 12.1% | 0.37 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| LLY Eli Lilly and Company compare | 21.0% |
| AMGN Amgen Inc. compare | 10.1% |
| AZN AstraZeneca PLC compare | 9.41% |
| NVS Novartis AG compare | 8.94% |
| JNJ Johnson & Johnson | 8.25% |
| ABBV AbbVie Inc. compare | 7.32% |
| PFE Pfizer Inc. compare | 1.95% |
| MRK Merck & Co., Inc. compare | 0.00% |
| GILD Gilead Sciences, Inc. compare | −7.03% |
| Drug Manufacturers General industry median | 2.28% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on JNJ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement